Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 641 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: velcade Clear all
Active, not recruiting Phase 3 Interventional

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

NCT00734877
View directory record Official record
Conditions
Multiple Myeloma
Interventions
M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

NCT01315873
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Bortezomib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

NCT02441686
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
8
States / cities
Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

NCT06083922
View directory record Official record
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
Interventions
Cyclophosphamide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00028587
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 22, 2026, 2:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Not applicable Interventional Results available

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

NCT00772668
View directory record Official record
Conditions
Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Rituximab, Bortezomib, Cyclophosphamide, Prednisone
Drug
Lead sponsor
University of Miami
Other
Eligibility
17 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

NCT05470491
View directory record Official record
Conditions
HIV, Hematologic Malignancies
Interventions
RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

NCT01568866
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Bortezomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
27
States / cities
Burbank, California • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

NCT00369707
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituximab, bortezomib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 3 Interventional

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

NCT04566328
View directory record Official record
Conditions
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
640
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NCT01470131
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Masitinib, Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Galesburg, Illinois • Bethesda, Maryland • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Results available

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT01088048
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
11
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

NCT00715208
View directory record Official record
Conditions
Relapsed Follicular Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, VELCADE, prednisone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
42
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

NCT00093756
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
143
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 3 Interventional

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

NCT00111319
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

UARK 2003-33, Total Therapy III

NCT00081939
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00624936
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Vidaza, Velcade
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00075881
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

NCT02874742
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
36
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 22, 2026, 2:34 PM EDT